Our finding that BRCA2 mutations were significantly more frequent in the GR group is in accordance with evidence that mutations in BRCA1 and especially BRCA2, confer chemo‐sensitivity in ovarian cancer.5 This evidence concerns the gene BRCA2 and ovarian cancer.